Impact of Immunotherapy on Liver Metastasis

Overview

Journal World J Gastrointest Surg

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2024 Aug 1

PMID 39087120

Authors

Zhuo Fu

Ming-Wei Wang

Ya-Hui Liu

Yan Jiao

Affiliations

Soon will be listed here.

Abstract

This editorial discusses the article "Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis" published in the latest edition of the . Immunotherapy has achieved outstanding success in tumor treatment. However, the presence of liver metastasis (LM) restrains the efficacy of immunotherapy in various tumors, including lung cancer, colorectal cancer, renal cell carcinoma, melanoma, and gastric cancer. A decrease in CD8+ T cells and nature killer cells, along with an increase in macrophages and regulatory T cells, was observed in the microenvironment of LM, leading to immunotherapy resistance. More studies are necessary to determine the best strategy for enhancing the effectiveness of immunotherapy in patients with LM.

References

Park J, Kim J . Pathologic differential diagnosis of metastatic carcinoma in the liver. Clin Mol Hepatol. 2018; 25(1):12-20. PMC: 6435968. DOI: 10.3350/cmh.2018.0067. View

Guillerey C . NK Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1273:69-90. DOI: 10.1007/978-3-030-49270-0_4. View

Schoenfeld A, Hellmann M . Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020; 37(4):443-455. PMC: 7182070. DOI: 10.1016/j.ccell.2020.03.017. View

Zhang J, Zhou X, Hao H . Macrophage phenotype-switching in cancer. Eur J Pharmacol. 2022; 931:175229. DOI: 10.1016/j.ejphar.2022.175229. View

Farhood B, Najafi M, Mortezaee K . CD8 cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2018; 234(6):8509-8521. DOI: 10.1002/jcp.27782. View

Wang J, Lei K, Han F . Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci. 2018; 22(12):3855-3864. DOI: 10.26355/eurrev_201806_15270. View

Belli C, Trapani D, Viale G, DAmico P, Duso B, Della Vigna P . Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018; 65:22-32. DOI: 10.1016/j.ctrv.2018.02.004. View

Najafi M, Goradel N, Farhood B, Salehi E, Shabani Nashtaei M, Khanlarkhani N . Macrophage polarity in cancer: A review. J Cell Biochem. 2018; 120(3):2756-2765. DOI: 10.1002/jcb.27646. View

Majidpoor J, Mortezaee K . Steps in metastasis: an updated review. Med Oncol. 2021; 38(1):3. DOI: 10.1007/s12032-020-01447-w. View

10.

Yu J, Green M, Li S, Sun Y, Journey S, Choi J . Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021; 27(1):152-164. PMC: 8095049. DOI: 10.1038/s41591-020-1131-x. View

11.

Yin W, Ma S, Dong Z, Xu M, Mao W . Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy. Cancer Manag Res. 2021; 13:4541-4551. PMC: 8197666. DOI: 10.2147/CMAR.S310331. View

12.

Zhang Q, Liu S, Liu Y, Bhatt D, Estrada J, Belmontes B . Liver Metastasis Modulate Responses of Suppressive Macrophages and Exhausted T Cells to Immunotherapy Revealed by Single Cell Sequencing. Adv Genet (Hoboken). 2023; 3(4):2200002. PMC: 9993474. DOI: 10.1002/ggn2.202200002. View

13.

Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z . The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Front Oncol. 2020; 10:546604. PMC: 7552942. DOI: 10.3389/fonc.2020.546604. View

14.

Wang C, Sandhu J, Ouyang C, Ye J, Lee P, Fakih M . Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. JAMA Netw Open. 2021; 4(8):e2118416. PMC: 8353537. DOI: 10.1001/jamanetworkopen.2021.18416. View

15.

Li C, Jiang P, Wei S, Xu X, Wang J . Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020; 19(1):116. PMC: 7367382. DOI: 10.1186/s12943-020-01234-1. View

16.

Vesely M, Zhang T, Chen L . Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annu Rev Immunol. 2022; 40:45-74. DOI: 10.1146/annurev-immunol-070621-030155. View

17.

Santhakumar C, Gane E, Liu K, McCaughan G . Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatol Int. 2020; 14(6):947-957. DOI: 10.1007/s12072-020-10104-3. View

18.

Kim S, Kim J, Park E, Joo J, Lee K, Seo H . Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy. PLoS One. 2019; 14(2):e0211105. PMC: 6382149. DOI: 10.1371/journal.pone.0211105. View

19.

Huang X, Chen Z, Zhang N, Zhu C, Lin X, Yu J . Increase in CD4FOXP3 regulatory T cell number and upregulation of the HGF/c-Met signaling pathway during the liver metastasis of colorectal cancer. Oncol Lett. 2020; 20(3):2113-2118. PMC: 7400973. DOI: 10.3892/ol.2020.11785. View

20.

Todryk S, Jozwik A, de Havilland J, Hester J . Emerging Cellular Therapies: T Cells and Beyond. Cells. 2019; 8(3). PMC: 6468692. DOI: 10.3390/cells8030284. View